Replies to post #119736 on Biotech Values

[biomaven0]

30% of AML is a way bigger indication than CML.

There's a drug from Ambit Bioscience partnered with Astellas called AC220 that claims to have similar potency that is going after these patients:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756206/?tool=pubmed

I think that drug is in Phase III, so it's well ahead of pona.

Peter